MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Genomic Health Company Profile (NASDAQ:GHDX)

Consensus Ratings for Genomic Health (NASDAQ:GHDX) (?)
Ratings Breakdown: 1 Sell Rating(s), 2 Hold Rating(s), 5 Buy Rating(s)
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $33.50 (25.28% upside)

Analysts' Ratings History for Genomic Health (NASDAQ:GHDX)
Show:
DateFirmActionRatingPrice TargetActions
6/21/2016Leerink SwannReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/1/2016Canaccord GenuityUpgradeHold -> Buy$44.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016Jefferies GroupReiterated RatingHold$24.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016Cowen and CompanyReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016Barclays PLCLower Price TargetUnderweight$27.00 -> $25.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2016Piper Jaffray Cos.Reiterated RatingIn-Line$32.00 -> $31.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/4/2015Raymond James Financial Inc.UpgradeMarket Perform -> Outperform$29.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/2/2015JMP SecuritiesBoost Price TargetOutperform$34.00 -> $36.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/28/2015Credit Suisse Group AGReiterated RatingNeutralView Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/11/2015William BlairReiterated RatingOutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/19/2014Wells Fargo & Co.Initiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/5/2014Bank of America Corp.Reiterated RatingBuy$28.00 -> $30.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for Genomic Health (NASDAQ:GHDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/4/2016Q1($0.24)($0.19)$78.12 million$80.89 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2016Q415($0.09)($0.10)$74.03 million$74.50 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/3/2015Q315($0.18)($0.36)$73.35 million$73.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.27)($0.29)$71.65 million$70.60 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/5/2015Q115($0.26)($0.30)$68.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/10/2015Q414($0.22)($0.20)$72.20 million$69.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2014Q314($0.22)($0.20)$71.00 million$69.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/5/2014Q214($0.26)($0.15)$69.04 million$70.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/6/2014Q114($0.18)($0.24)$68.47 million$67.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/4/2014Q413($0.03)($0.30)$69.20 million$68.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2013Q313($0.04)$0.02$64.98 million$65.99 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/31/2013Q2 2013($0.08)($0.10)$63.91 million$63.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2013Q1 2013($0.02)($0.03)$62.90 million$63.10 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2013Q4 2012$0.03$0.06$58.90 million$60.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312$0.05$0.11$59.87 million$58.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2012($0.02)$0.06ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/2/2012($0.02)$0.02ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/6/2012$0.09$0.08ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/1/2011$0.03$0.10ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/3/2011$0.02$0.08ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2011$0.02($0.01)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/8/2011$0.06$0.06ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Genomic Health (NASDAQ:GHDX)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20165($0.25)($0.07)($0.17)
Q2 20167($0.20)($0.01)($0.11)
Q3 20165($0.15)$0.01($0.04)
Q4 20167($0.02)$0.04$0.01
(Data provided by Zacks Investment Research)
Dividend History for Genomic Health (NASDAQ:GHDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Genomic Health (NASDAQ:GHDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
6/21/2016Steven ShakInsiderSell5,000$25.77$128,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2016G Bradley ColeCOOSell5,000$26.62$133,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/6/2016James J VaughnInsiderSell1,997$28.00$55,916.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2016G Bradley ColeCOOSell5,000$27.60$138,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/10/2016Phillip G FebboInsiderSell6,324$27.20$172,012.80View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/4/2016Steven ShakInsiderSell10,000$25.43$254,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2016Randall S. LivingstonDirectorSell1,250$32.14$40,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2016G Bradley ColeCOOSell4,000$31.69$126,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2016James J. VaughninsiderSell2,000$33.63$67,260.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015G Bradley ColeCOOSell4,000$29.26$117,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015James J. VaughninsiderSell2,000$29.33$58,660.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/10/2015G Bradley ColeCOOSell4,000$26.03$104,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2015G Bradley ColeCOOSell9,664$25.35$244,982.40View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2015G Bradley ColeCOOSell4,000$27.53$110,120.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/9/2015G Bradley ColeCOOSell4,000$26.24$104,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/13/2015Kimberly J PopovitsCEOSell3,000$31.28$93,840.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/7/2015G Bradley ColeCOOSell4,000$30.44$121,760.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/2/2015Randall S LivingstonDirectorSell1,000$31.93$31,930.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/12/2015Kimberly J PopovitsCEOSell3,000$33.46$100,380.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2014G Bradley ColeCOOSell4,336$32.52$141,006.72View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2014Kimberly J PopovitsCEOSell4,300$34.82$149,726.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/13/2014Kimberly J PopovitsCEOSell3,000$30.78$92,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/8/2014G Bradley ColeCOOSell4,000$28.77$115,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/11/2014Kimberly J PopovitsCEOSell3,000$29.82$89,460.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/8/2014G Bradley ColeCOOSell4,700$30.09$141,423.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Steven ShakEVPSell13,348$27.36$365,201.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Steven ShakEVPSell7,000$27.25$190,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/14/2014Kimberly J PopovitsCEOSell3,000$26.59$79,770.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2014G Bradley ColeCOOSell2,300$27.05$62,215.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2014Steven ShakEVPSell7,000$27.00$189,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/14/2014Steven ShakEVPSell7,000$26.25$183,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
4/8/2014G Bradley ColeCOOSell3,000$27.00$81,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2014Steven ShakEVPSell7,000$28.36$198,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/18/2014Kathy HibbsSVPSell1,312$27.88$36,578.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/15/2014Steven ShakEVPSell7,000$31.51$220,570.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/13/2014Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/17/2013Steven ShakCMOSell14,000$29.57$413,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/12/2013Kimberly PopovitsCEOSell2,500$30.68$76,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2013Dean SchornoCFOSell3,000$33.25$99,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/15/2013Steven ShakCMOSell5,000$29.67$148,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/10/2013Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/9/2013G Bradley ColeCOOSell2,500$29.95$74,875.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/18/2013Steven ShakCMOSell5,000$33.73$168,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2013Kimberly PopovitsCEOSell2,500$34.31$85,775.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/9/2013G Bradley ColeCOOSell2,500$32.53$81,325.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/6/2013Dean L SchornoCFOSell4,000$32.90$131,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Randall LivingstonDirectorSell1,000$31.49$31,490.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2013Steven ShakCMOSell5,000$32.98$164,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/12/2013Kimberly PopovitsCEOSell2,500$33.03$82,575.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/9/2013Dean SchornoCFOSell4,000$33.15$132,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/7/2013G Bradley ColeCOOSell2,500$33.66$84,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/23/2013Steven ShakCMOSell5,000$35.33$176,650.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/12/2013Kimberly J PopovitsCEOSell5,000$34.61$173,050.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/9/2013Dean L SchornoCFOSell4,000$33.81$135,240.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2013G Bradley ColeCOOSell2,500$33.33$83,325.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2013Steven ShakCMOSell5,000$33.52$167,600.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/12/2013Kimberly J PopovitsCEOSell5,000$35.68$178,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/10/2013Dean L SchornoCFOSell4,000$35.88$143,520.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013Felix BakerDirectorBuy381,432$36.16$13,792,581.12View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/5/2013G Bradley ColeCOOSell2,500$36.47$91,175.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Felix BakerDirectorBuy179,583$36.71$6,592,491.93View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/29/2013Felix BakerDirectorBuy121,266$36.89$4,473,502.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/24/2013Felix BakerDirectorBuy79,417$36.93$2,932,869.81View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2013Kathy L HibbsSVPSell1,000$37.48$37,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/21/2013Steven ShakCMOSell5,000$37.19$185,950.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/16/2013Felix BakerDirectorBuy71,439$36.45$2,603,951.55View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2013Randall S LivingstonDirectorSell1,337$35.83$47,904.71View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2013Felix BakerDirectorBuy240,426$34.34$8,256,228.84View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013Kathy L HibbsSVPSell1,250$34.42$43,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/13/2013Kimberly J PopovitsCEOSell5,000$34.70$173,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/9/2013Dean L SchornoCFOSell4,000$36.02$144,080.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/8/2013G Bradley ColeCOOSell2,500$35.99$89,975.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/21/2013Felix BakerDirectorBuy49,085$27.78$1,363,581.30View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/14/2013Woodrow A Myers JrDirectorSell41,250$28.40$1,171,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
2/11/2013Felix BakerDirectorBuy116,360$28.15$3,275,534.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/26/2012Randall S LivingstonDirectorSell2,000$27.84$55,680.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/21/2012Felix BakerDirectorBuy229,300$26.83$6,152,119.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/14/2012Felix BakerDirectorBuy103,167$27.32$2,818,522.44View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/13/2012Felix BakerDirectorBuy823,772$27.81$22,909,099.32View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/12/2012Dean L SchornoCFOSell3,000$28.00$84,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/8/2012G Bradley ColeCOOSell2,500$28.62$71,550.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Genomic Health (NASDAQ:GHDX)
DateHeadline
06/30/16 04:30 PMGenomic Health Incorporated (NASDAQ:GHDX) Shorts Decreased by 4% After Short Covering - Press Telegraph
06/30/16 07:03 AMGenomic Health, Inc. (NASDAQ:GHDX) Company Rating and Target Watch - Telanagana Press
06/29/16 04:16 AMShare Update and Earnings Review for Genomic Health, Inc. (NASDAQ:GHDX) - Press Telegraph
06/28/16 09:02 AMGenomic Health, Inc. (NASDAQ:GHDX) Earnings Glance and Target Price Review - Engelwood Daily
06/27/16 08:39 AMNext Weeks Broker Price Targets For Genomic Health, Inc. (NASDAQ:GHDX) - Fiscal Standard
06/26/16 03:43 PMWhy America's Advantage Is Innovation (CHKP, GHDX)
06/25/16 03:58 PMStrong Sell Calls Recommendations For Genomic Health, Inc. (NASDAQ:GHDX) At 1 - Investor Newswire
06/24/16 07:50 AMGenomic Health: Can the Liquid Biopsy Test Boost Margins? -
06/23/16 03:08 PMGENOMIC HEALTH INC Files SEC form 8-K, Change in Directors or Principal Officers -
06/20/16 10:28 AMThis Weeks Broker Views For Genomic Health, Inc. (NASDAQ:GHDX) - Fiscal Standard
06/19/16 08:30 AMStrong Buy Calls Count For Genomic Health, Inc. (NASDAQ:GHDX) At 5 - Investor Newswire
06/17/16 07:13 AMGenomic Health Brings Liquid Biopsy Test for Stage IV Cancer -
06/15/16 04:21 PMGENOMIC HEALTH INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/14/16 07:00 AMGenomic Health Launches Oncotype SEQ™ Liquid Biopsy Mutation Panel - [PR Newswire] - REDWOOD CITY, Calif., June 14, 2016 /PRNewswire/ -- Genomic Health, Inc. (GHDX) today announced the commercial launch of Oncotype SEQ™ Liquid Select, the first of several non-invasive liquid biopsy tests that the company plans to deliver through its Oncotype IQ™ Genomic Intelligence Platform. Oncotype SEQ is a blood-based test that uses next-generation sequencing to identify and assess actionable genomic alterations in a panel of 17 select genes to inform the treatment of stage IV solid tumors, including lung, breast, colon, melanoma, ovarian, and gastrointestinal stromal tumors. The test is designed to provide clinically actionable information focused on genomic markers that have either been included in National Comprehensive Cancer Network (NCCN®) guidelines or associated with sensitivity or resistance to relevant FDA-approved therapies.
06/10/16 04:20 PMBrokers Issue Average Price Target Of 31.82 On Genomic Health, Inc. (NASDAQ:GHDX) - Fiscal Standard
06/10/16 04:44 AMGenomic Health, Inc. (NASDAQ:GHDX) Earns Rating Score Of 2.27 - RealistInvestor.com
06/09/16 05:13 AMGenomic Health (GHDX) Announces Publication of Results from NCI Surveillance, Epidemiology, and End Results ... - StreetInsider.com
06/08/16 03:05 PMNature Partner Journals Publish Five-year Outcomes Results from SEER Registry Demonstrating Oncotype DX® Accurately Identifies Early-stage Breast Cancer Patients with Excellent Survival - [PR Newswire] - REDWOOD CITY, Calif., June 8, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the publication of results from the National Cancer Institute's (NCI) Surveillance, Epidemiology, ...
06/07/16 09:55 PMGenomic Health, Inc. (NASDAQ:GHDX) Low Price Is Set At $25 - RealistInvestor.com
06/07/16 09:55 PMGenomic Health Inc. (GHDX) Jumps 6.16% on June 06 - Equities.com
06/05/16 04:08 PMGenomic Health Announces Multiple Oncotype DX® Presentations at ASCO 2016 Showcasing Industry-leading ... - PR Newswire (press release)
06/05/16 07:00 AMGenomic Health Announces Multiple Oncotype DX® Presentations at ASCO 2016 Showcasing Industry-leading Commitment to Bringing Precision Medicine to Cancer Patients - [PR Newswire] - REDWOOD CITY, Calif., June 5, 2016 /PRNewswire/ -- Genomic Health, Inc. (GHDX) today announced results from seven Oncotype DX® studies being presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting. Results include four new analyses from the National Cancer Institute's (NCI) Surveillance, Epidemiology, and End Results (SEER) Registry with more than 44,600 breast cancer patients. The SEER analyses reconfirmed through prospective outcomes data that the Oncotype DX® Breast Recurrence Score™ is an accurate predictor of five-year survival in patients with node-positive and node-negative disease in contemporary "real-world" clinical practice and revealed disparities in Oncotype DX testing use and patient outcomes.
06/02/16 10:21 PMGenomic Health, Inc. (NASDAQ:GHDX) Stock Update & Estimates - Stock Tick Tock - Genomic Health, Inc. (NASDAQ:GHDX) Stock Update & EstimatesStock Tick TockThe consensus on Wall Street is expecting Genomic Health, Inc. (NASDAQ:GHDX) to post earnings of $-0.18 per share when the firm next reports it's fiscal quarterly results. According to the latest information available the report will likely be issued ...and more »
06/02/16 04:49 AMCanaccord Genuity Upgrades Genomic Health, Inc. (GHDX) to “Buy” - Let Me Know About This - Canaccord Genuity Upgrades Genomic Health, Inc. (GHDX) to “Buy”Let Me Know About ThisGenomic Health logo Genomic Health, Inc. (NASDAQ:GHDX) was upgraded by research analysts at Canaccord Genuity from a “hold” rating to a “buy” rating in a report released on Wednesday, StockTargetPrices.com reports. The brokerage currently has a ...Broker Watchlist: Genomic Health, Inc. (NASDAQ:GHDX)Share Trading Newsall 3 news articles »
05/31/16 04:23 PMThe Growth Forecast For Genomic Health, Inc. (NASDAQ:GHDX) - RealistInvestor.com - The Growth Forecast For Genomic Health, Inc. (NASDAQ:GHDX)RealistInvestor.comWall Street renowned brokerages following Genomic Health, Inc. (NASDAQ:GHDX) have now given a mean price target of $32.166 on its stock. After accomplishing a methodical study, the analysts have specified a target price range. The intense high range is ...Genomic Health to Present at Jefferies 2016 Healthcare ConferencePR Newswire (press release)all 2 news articles »
05/31/16 08:52 AMGenomic Health to Present at Jefferies 2016 Healthcare Conference - PR Newswire (press release) - Genomic Health to Present at Jefferies 2016 Healthcare ConferencePR Newswire (press release)REDWOOD CITY, Calif., May 31, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, Chief Operating Officer and Chief Financial Officer, will present at the Jefferies 2016 Healthcare Conference at the Grand Hyatt in ...and more »
05/31/16 07:00 AMGenomic Health to Present at Jefferies 2016 Healthcare Conference - [PR Newswire] - REDWOOD CITY, Calif., May 31, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole , Chief Operating Officer and Chief Financial Officer, will present at the Jefferies ...
05/27/16 12:27 AMGenomic Health, Inc. (NASDAQ:GHDX) Closes At $26.20 - RealistInvestor.com - Genomic Health, Inc. (NASDAQ:GHDX) Closes At $26.20RealistInvestor.comThe technical analysis of Genomic Health, Inc. (NASDAQ:GHDX) stock highlights the stock is $-0.67 points away -2.48% from its 50-day MA of $26.86. It is $-1.80 or -6.44% away $27.99, the 200-day Moving Average (MA) of stock. Yesterday, the stock of ...Earnings Recap: Genomic Health (GHDX)CWRU ObserverGenomic Health, Inc. (NASDAQ:GHDX): Analysts Quick Take on EarningsNews TribuneGenomic Health (GHDX) Announces Publication of Positive Oncotype DX Data in ASCO JournalStreetInsider.comSonoran Weekly Review -PR Newswire (press release)all 8 news articles »
05/26/16 07:13 PMGenomic Health (GHDX) to Present Additional Oncotype DX Data at ASCO 2016 - Claim your 2-week free trial to StreetInsider Premium here. Genomic Health, Inc. (Nasdaq: GHDX) announced that the company will present results from seven Oncotype DX® studies at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting ...
05/26/16 07:00 AMGenomic Health Announces Presentation of Seven Oncotype DX® Studies at the 2016 American Society of Clinical Oncology Annual Meeting, Including Additional Prospective Outcomes Analysis - [PR Newswire] - REDWOOD CITY, Calif., May 26, 2016 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from seven Oncotype DX ® studies at the 2016 American Society ...
05/25/16 06:55 PMGenomic Health (GHDX) Announces Publication of Positive Oncotype DX Data in ASCO Journal - StreetInsider.com - Genomic Health (GHDX) Announces Publication of Positive Oncotype DX Data in ASCO JournalStreetInsider.comGenomic Health, Inc. (Nasdaq: GHDX) announced that the Journal of Clinical Oncology, the official journal of the American Society of Clinical Oncology (ASCO), published results from a large study confirming the ability of the Oncotype DX® Breast ...Genomic Health Says Study Confirms Oncotype DX Predicts Late Distant Recurrence in Breast Cancer (NASDAQ:GHDX)Sonoran Weekly Reviewall 4 news articles »
05/25/16 07:04 AM8:04 am Genomic Health announces Oncotype DX predicts late distant recurrence in breast cancer, results published in Journal of Clinical Oncology -
05/25/16 07:00 AMGenomic Health Announces Publication in Journal of Clinical Oncology Demonstrating Oncotype DX® Predicts Late Distant Recurrence in Breast Cancer - [PR Newswire] - REDWOOD CITY, Calif., May 25, 2016 /PRNewswire/ -- Genomic Health, Inc. (GHDX) today announced that the Journal of Clinical Oncology, the official journal of the American Society of Clinical Oncology (ASCO), published results from a large study confirming the ability of the Oncotype DX® Breast Recurrence Score™, in combination with quantitative estrogen-receptor (ER) expression, to accurately predict after five years of tamoxifen therapy the risk of late distant recurrence up to 15 years in patients with early-stage, hormone receptor-positive breast cancer. "Extending tamoxifen treatment for 10 years has been shown to be associated with better outcomes, but not all patients have the same risk of late distant recurrence – meaning cancer coming back after five years – and it is important to know a patient's risk in order to better understand who will benefit the most from extended hormonal treatment," said Norman Wolmark, M.D., chairman of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation, the organization that carried out the study in conjunction with Genomic Health.
05/23/16 12:18 PMStock Rating Review for Genomic Health, Inc. (NASDAQ:GHDX) - Wall Street Hints and News - Stock Rating Review for Genomic Health, Inc. (NASDAQ:GHDX)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 2.27 on shares of Genomic Health, Inc. (NASDAQ:GHDX). Covering analysts ...and more »
05/22/16 11:44 AMGenomic Health, Inc. Can't Be More Safe. Trades Significantly Higher - Wall Street Hints and News - Genomic Health, Inc. Can't Be More Safe. Trades Significantly HigherWall Street Hints and NewsThe stock of Genomic Health, Inc. (NASDAQ:GHDX) is a huge mover today! The stock increased 5.35% or $1.28 on May 20, hitting $25.19. About 331,675 shares traded hands or 63.48% up from the average. Genomic Health, Inc. (NASDAQ:GHDX) has risen ...After Recent Decline, is it Time to Sell Genomic Health Inc. (NASDAQ:GHDX)Franklin Independentall 3 news articles »
05/21/16 12:06 AMGenomic Health Inc. (GHDX) Jumps 5.35% on May 20 - Equities.com - Genomic Health Inc. (GHDX) Jumps 5.35% on May 20Equities.comGenomic Health Inc. (GHDX) was among the biggest gainers on the Russell 2000 for Friday May 20 as the stock popped 5.35% to $25.19, representing a gain of $1.28 per share. Some 331,023 shares traded hands on 3,235 trades, compared with an average ...and more »
05/19/16 06:59 PMToday's Weak On High Volume Stock: Genomic Health (GHDX) - TheStreet.com - TheStreet.comToday's Weak On High Volume Stock: Genomic Health (GHDX)TheStreet.comEXCLUSIVE OFFER: Get the inside scoop on opportunities in GHDX with the Ticky from Trade-Ideas. See the FREE profile for GHDX NOW at Trade-Ideas. More details on GHDX: Genomic Health, Inc., a healthcare company, provides actionable genomic ...and more »
05/19/16 06:59 PMGenomic Health Inc. (GHDX) Drops 8.94% on May 18 - Equities.com - Genomic Health Inc. (GHDX) Drops 8.94% on May 18Equities.comGenomic Health Inc. (GHDX) was one of the Russell 2000's biggest losers for Wednesday May 18 as the stock slid 8.94% to $24.97, a loss of $-2.45 per share. Starting at an opening price of $26.72 a share, the stock traded between $24.82 and $26.73 over ...and more »
05/19/16 06:29 PMETF’s with exposure to Genomic Health, Inc. : May 19, 2016 -
05/19/16 08:00 AMGenomic Health, Inc. breached its 50 day moving average in a Bearish Manner : GHDX-US : May 19, 2016 -
05/19/16 12:11 AMBradley Cole Insider Deal for 5000 Shares of Genomic Health, Inc. (NASDAQ:GHDX) - Wall Street Hints and News - Bradley Cole Insider Deal for 5000 Shares of Genomic Health, Inc. (NASDAQ:GHDX)Wall Street Hints and NewsBradley Cole, COO of Genomic Health Inc, in an insider legal trade sold 5,000 shares whose value is estimated to be $137,995 at average stock price of $27.6. He also unloaded shares worth about $ USD in the last 30 days. Right now, Bradley Cole has a ...Genomic Health, Inc. (NASDAQ:GHDX) Trading Down - Insider Trading ActivityFinance Dailyall 2 news articles »
05/18/16 11:26 AMShare Recap and Earnings Focus on Genomic Health, Inc. (NASDAQ:GHDX) - Wall Street Hints and News - Share Recap and Earnings Focus on Genomic Health, Inc. (NASDAQ:GHDX)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating Genomic Health, Inc.and more »
05/17/16 11:53 PMShare Performance and Target Price Review for Genomic Health, Inc. (NASDAQ:GHDX) - Wall Street Hints and News - Share Performance and Target Price Review for Genomic Health, Inc. (NASDAQ:GHDX)Wall Street Hints and NewsLooking at stock activity from multiple angles may be of benefit when examining share performance. Investors have the ability to focus in on short or long term share performance. During the most recent trading session, Genomic Health, Inc. (NASDAQ:GHDX ...and more »
05/16/16 12:24 PMConsensus Rating Review for Genomic Health, Inc. (NASDAQ:GHDX) - Wall Street Hints and News - Consensus Rating Review for Genomic Health, Inc. (NASDAQ:GHDX)Wall Street Hints and NewsEquity research analysts currently have a consensus rating of 2.27 on shares of Genomic Health, Inc. (NASDAQ:GHDX). Sell-side analysts will typically rate a company's stock based on extensive research. These ratings usually translate into a Buy, Sell, ...and more »
05/16/16 12:24 PMNext Weeks Broker Price Targets For Genomic Health, Inc. (NASDAQ:GHDX) - Share Trading News - Next Weeks Broker Price Targets For Genomic Health, Inc. (NASDAQ:GHDX)Share Trading News02/11/2016 – Genomic Health, Inc. had its “neutral” rating reiterated by analysts at Piper Jaffray. They now have a USD 31 price target on the stock. 01/20/2016 – Genomic Health, Inc. had its “outperform” rating reiterated by analysts at Leerink Swann.Genomic Health Incorporated (NASDAQ:GHDX) Shorts Decreased by 2.33% After Short CoveringWall Street Hints and Newsall 2 news articles »
05/13/16 07:19 PMGenomic Health, Inc. (NASDAQ:GHDX) One-Year Mean Price Target At $32.166 - Stocks Daily - Genomic Health, Inc. (NASDAQ:GHDX) One-Year Mean Price Target At $32.166Stocks DailySell-side analysts are confident on the future outlook of Genomic Health, Inc. (NASDAQ:GHDX) stock. As of 2016-05-12, the stock has an ABR of 2.27 rating, where number 5 denotes a Strong Sell and 1 Strong Buy. The ABR is reached on the basis of ...and more »
05/10/16 07:28 PMBuy Recommendations Count For Genomic Health, Inc. (NASDAQ:GHDX) At 1 - Investor Newswire - Buy Recommendations Count For Genomic Health, Inc. (NASDAQ:GHDX) At 1Investor NewswireGenomic Health, Inc. (NASDAQ:GHDX) has a total of 5 Strong Buy recommendations and 1 Strong Sell recommendations as of 2016-05-09. One month earlier, the strong buy calls were 5 and strong sell count was 1. The mean analyst rating was 2.33.and more »
05/10/16 07:28 PMPerformance Recap and Target Perspective on Genomic Health, Inc. (NASDAQ:GHDX) - B.O.D.Y Confidential - Performance Recap and Target Perspective on Genomic Health, Inc. (NASDAQ:GHDX)B.O.D.Y ConfidentialIn the latest trading session, shares of Genomic Health, Inc. (NASDAQ:GHDX) moved +1.80%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a recent check, company ...and more »
05/10/16 07:07 PMGenomic Health, Inc. Earnings: Waiting for (More) Reimbursement -
05/09/16 07:10 PMCheck on Analyst Ratings Genomic Health, Inc. (NASDAQ:GHDX) - B.O.D.Y Confidential - Check on Analyst Ratings Genomic Health, Inc. (NASDAQ:GHDX)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 2.27 on shares of Genomic Health, Inc. (NASDAQ:GHDX). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on a 1 to 5 scale.and more »
About Genomic Health

Genomic Health logoGenomic Health, Inc. is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer. Its Oncotype DX tests utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. It offers its services and products, including Oncotype DX Breast Cancer Test, Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test through its Oncotype IQ Genomic Intelligence Platform.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Laboratories & Research
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: GHDX
  • CUSIP: 37244C10
Key Metrics:
  • Previous Close: $26.74
  • 50 Day Moving Average: $26.25
  • 200 Day Moving Average: $27.57
  • P/E Ratio: N/A
  • P/E Growth: -10.46
  • Market Cap: $882.82M
  • Current Quarter EPS Consensus Estimate: $-0.45 EPS
Additional Links:
Genomic Health (NASDAQ:GHDX) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha